Harmony Biosciences Holdings, Inc. (HRMY)
HRMY moved a median of -0.06% 30 minutes after news, and +0.37% by the close. How HRMY actually reacts to news — the realized, point-in-time move the market made, measured across 385 labeled events over the last three years with zero look-ahead.
HRMY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 383 |
| 30-min | -0.06% | 48% | 383 |
| 60-min | +0.05% | 51% | 383 |
| to close | +0.37% | 56% | 382 |
| Middle 50% of HRMY reactions | -0.83% to +0.92% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 385 |
Half of all Harmony Biosciences Holdings, Inc. news events land between -0.83% and +0.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HRMY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.06% | 50% | -0.18% |
| Analyst downgrades | 17 | -1.07% | 18% | -1.32% |
| Coverage initiations | 22 | +0.09% | 55% | -0.27% |
| Rating reiterations | 108 | +0.35% | 62% | +0.58% |
| Price-target raises | 12 | +0.05% | 58% | +0.84% |
| Price-target cuts | 15 | +0.18% | 60% | +1.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how HRMY ranks against every other measured name →
That’s how HRMY usually reacts — get an email when it moves on news →Email me when HRMY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HRMY's baseline. Nothing else.
Recent HRMY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Harmony Biosciences Hold For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | -2.32% | |
| Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth | Press release | GlobeNewswire | -0.68% | -0.29% | |
| Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | Press release | GlobeNewswire | +0.15% | -0.03% | |
| Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress | Press release | GlobeNewswire | +1.11% | -2.49% | |
| Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | -0.55% | +0.35% | |
| Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium | Press release | GlobeNewswire | -0.03% | +1.15% | |
| Form 10-Q Harmony Biosciences Hold For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.85% | +2.62% | |
| Form 8-K Harmony Biosciences Hold For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | +2.62% | |
| Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | Press release | GlobeNewswire | -1.85% | +2.62% | |
| Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | Press release | GlobeNewswire | +0.42% | +10.76% | |
| Form 8-K Harmony Biosciences Hold For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +1.79% | |
| Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition | Press release | Business Wire | +0.73% | +1.79% | |
| Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting | Press release | Business Wire | +0.34% | -1.10% | |
| Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical | Press release | Business Wire | -0.10% | -0.20% | |
| Harmony Biosciences to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.00% | +1.18% | |
| Form 8-K Harmony Biosciences Hold For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | -2.62% | |
| Form 10-Q Harmony Biosciences Hold For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.06% | +8.53% | |
| Form 8-K Harmony Biosciences Hold For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +4.06% | +8.53% | |
| Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities | Press release | Business Wire | +4.06% | +8.53% | |
| Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | +0.61% | +0.28% | |
| Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting | Press release | Business Wire | +1.05% | +1.45% | |
| Form 8-K Harmony Biosciences Hold For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +1.62% | +1.88% | |
| Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer | Press release | Business Wire | +1.62% | +1.88% | |
| Form ARS Harmony Biosciences Hold For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.35% | -0.47% | |
| Form DEF 14A Harmony Biosciences Hold For: May 14 | SEC filing · Form DEF | SEC EDGAR | -1.35% | -0.47% | |
| Form DEFA14A Harmony Biosciences Hold | SEC filing · Form DEFA14A | SEC EDGAR | -1.35% | -0.47% | |
| Form 8-K Harmony Biosciences Hold For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +1.09% | |
| Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board | Press release | Business Wire | -0.42% | +1.09% | |
| Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | +1.36% | +3.05% | |
| Harmony Biosciences to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.42% | -0.94% | |
| Form 10-K Harmony Biosciences Hold For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.16% | +1.92% | |
| Form 8-K Harmony Biosciences Hold For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -4.16% | +1.92% | |
| Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion | Press release | Business Wire | -4.16% | +1.92% | |
| Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy | Press release | Business Wire | +0.05% | +0.16% | |
| Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | Press release | Business Wire | -1.16% | +2.02% | |
| Form 8-K Harmony Biosciences Hold For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.40% | -2.84% | |
| Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation | Press release | Business Wire | -2.40% | -2.84% | |
| Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.15% | +1.02% | |
| Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG | Press release | GlobeNewswire | -0.94% | -1.70% | |
| Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome | Press release | Business Wire | -2.51% | -2.70% | |
| Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting | Press release | Business Wire | +0.89% | +1.21% | |
| Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation | Press release | Business Wire | -0.10% | +2.71% | |
| Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence | Press release | Business Wire | -1.12% | -1.71% | |
| Harmony Biosciences to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.03% | +0.41% | |
| Form 10-Q Harmony Biosciences Hold For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.25% | +4.81% | |
| Form 8-K Harmony Biosciences Hold For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -5.25% | +4.81% | |
| Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M | Press release | Business Wire | -5.25% | +4.81% | |
| Form 8-K Harmony Biosciences Hold For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | +5.26% | |
| Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance | Press release | Business Wire | -1.60% | +5.26% | |
| Form 8-K Harmony Biosciences Hold For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | -10.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HRMY section they belong to.
Where else HRMY is measured.
HRMY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Harmony Biosciences Holdings, Inc.'s median reaction calculated?
Every labeled HRMY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 385 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of HRMY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HRMY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.